Form 4: Travere Therapeutics Director Sells Shares

Travere Therapeutics Director Roy D. Baynes reported a sale of 10,000 shares of common stock for $26.52 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Director Roy D. Baynes of Travere Therapeutics, Inc. has reported a transaction involving common stock.
• On April 6, 2026, 10,000 shares of common stock were acquired at a price of $26.52 per share.
• The same day, 10,000 shares were disposed of at a price of $33.00 per share.
• This transaction was executed under a written trading plan adopted on November 17, 2025, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The disposed shares were part of a stock option grant from May 9, 2018, which was fully vested and exercisable.
• Following these transactions, the reporting person beneficially owns 37,500 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a director selling shares, the transaction was executed under a pre-arranged Rule 10b5-1 plan, mitigating concerns about immediate negative sentiment.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned and orderly disposition of shares rather than a reaction to immediate market conditions.
• The stock option, from which the disposed shares originated, was fully vested, meaning the director had the right to exercise it.
• The transaction involved the exercise of a stock option and subsequent sale, which is a common and often expected activity for executives and directors.

Negatives

• A significant number of shares (10,000) were sold by a director.
• The sale represents a disposition of equity, which could be interpreted negatively by the market if not contextualized by the Rule 10b5-1 plan.

Risks

• Potential for negative market perception regarding insider selling, even if conducted under a Rule 10b5-1 plan.
• The underlying stock option was exercised at a price of $26.52 and sold at $33.00, indicating a profit was realized, but the market may focus on the sale itself.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Management Comments

• The sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c).
• The sale consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2018.
• The stock option is fully vested and exercisable.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Travere Therapeutics' Director Roy D. Baynes is a common practice to facilitate planned stock sales while adhering to insider trading regulations, suggesting a structured approach to personal financial management rather than a signal of negative company outlook.

Stakeholder Impact

• Shareholders: May view insider selling with caution, though the Rule 10b5-1 plan provides a mitigating factor. The sale does not directly impact the company's operations or financial health.
• Employees: No direct impact.
• Creditors: No direct impact.
• Suppliers: No direct impact.
• Customers: No direct impact.

Next Steps

• Monitor future Form 4 filings for any additional insider transactions.
• Observe market reaction to this reported transaction, although the Rule 10b5-1 plan should limit significant impact.

Key Dates

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Beneficial Ownership, Director Transaction, Securities Sale